局部晚期肝细胞癌经放射栓塞或索拉菲尼治疗的健康相关生活质量:SARAH试验辅助研究
SARAH试验辅助研究比较局部晚期或不可手术肝细胞癌患者接受经动脉放射栓塞(TARE)或索拉菲尼后的健康相关生活质量(HRQoL)。纳入285例患者(TARE组122例,索拉菲尼组163例),使用EORTC QLQ-C30问卷评估。结果显示TARE组整体健康状况恶化中位时间3.9个月(95%CI 3.7-4.3),索拉菲尼组2.6个月(95%CI 2.0-3.0),TARE组HRQoL维持更久。
要点
- TARE组整体健康状况恶化中位时间3.9个月,长于索拉菲尼组的2.6个月。
- 疲劳和整体健康状况存在显著治疗与时间效应,食欲下降、腹泻和社交功能存在显著治疗、时间及交互效应。
- 两组问卷完成率相似(77.5% vs 80.4%,p=0.25)。
核心结论
- 在局部晚期肝细胞癌中,TARE较索拉菲尼能更长时间维持健康相关生活质量。
研究设计与样本
- SARAH试验的辅助研究,纳入接受TARE或至少一剂索拉菲尼、无重大方案偏离且除基线外至少有一次生活质量随访评估的随机患者,共285例(TARE组122例,索拉菲尼组163例)。
- 使用EORTC QLQ-C30问卷从随机化日期开始评估生活质量,直至疾病进展或其他停止研究参与的原因,采用线性混合模型和时间依赖模型分析。
主要发现
- 问卷完成率TARE组77.5%,索拉菲尼组80.4%,差异无统计学意义(p=0.25)。
- 纵向HRQoL分析显示疲劳和整体健康状况存在显著的治疗和时间效应。
- 食欲下降、腹泻和社交功能存在显著的治疗、时间及治疗与时间交互效应。
- 整体健康状况恶化中位时间TARE组3.9个月(95%CI 3.7-4.3),索拉菲尼组2.6个月(95%CI 2.0-3.0)。
临床怎么用
- 对于局部晚期或不可手术肝细胞癌患者,选择TARE可能有助于更长时间维持生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this ancillary study of the SARAH trial is to compare health-related quality of life (HRQoL) in patients with locally advanced or inoperable hepatocellular carcinoma (HCC) treated with transarterial radioembolisation (TARE) or sorafenib. METHODS: This study included randomised patients who received either TARE or at least one dose of sorafenib with no major deviation in the protocol and who had at least one QoL follow-up assessment in addition to the baseline evaluation. QoL was assessed from the date of randomisation using the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire, until disease progression or other reasons for stopping study participation. Data were analysed using linear mixed and time-dependent models. RESULTS: A total of 285 patients were included (122 and 163, in the TARE and sorafenib groups, respectively). Questionnaire completion rates were similar (77.5% versus 80.4%, in the TARE and sorafenib groups, respectively, p = 0.25). Longitudinal HRQoL analysis showed a significant treatment and time effects for fatigue and global health status, and significant treatment, time and treatment by time interaction effects for appetite loss, diarrhoea and social functioning. The median time to deterioration for the global health status was 3.9 months (95% confidence interval [CI] 3.7-4.3) versus 2.6 months (95% CI 2.0-3.0) in the TARE and sorafenib groups, respectively. CONCLUSIONS: HRQoL was preserved longer with TARE than with sorafenib in locally advanced HCC. These data could be used to optimise management of patients with advanced or inoperable HCC.
引用
- Pereira H, Bouattour M, Dioguardi Burgio M, et al. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial). Eur J Cancer. 2021. PMID: 34243077. doi:10.1016/j.ejca.2021.05.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。